Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple myeloma: recognition and management.

E D George1, R Sadovsky

  • 1State University of New York Health Science Center, Brooklyn 11203, USA.

American Family Physician
|April 20, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician.

International journal of clinical practice·2013
Same author

Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

International journal of clinical practice·2009
Same author

Impact of an educational initiative on applied knowledge and attitudes of physicians who treat sexual dysfunction.

International journal of impotence research·2008
Same author

Benign prostatic hyperplasia evaluation, treatment and association with sexual dysfunction: practice patterns according to physician specialty.

International journal of clinical practice·2008
Same author

Identification and diagnosis of premature ejaculation.

International journal of clinical practice·2007
Same author

Efficacy and safety of alfuzosin 10 mg once daily in the treatment of symptomatic benign prostatic hyperplasia.

International journal of clinical practice·2006
Same journal

For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

American family physician·2026
Same journal

Nausea and Vomiting During Pregnancy.

American family physician·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

American family physician·2026
Same journal

Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

American family physician·2026
Same journal

Overscreening Leads to Overdiagnosis of MASLD.

American family physician·2026
Same journal

Type 2 Diabetes: Outpatient Insulin Management.

American family physician·2026
See all related articles

Multiple myeloma, a plasma cell cancer, often presents with bone pain but can be diagnosed incidentally. Standard treatment offers limited response rates and a median survival of three years.

Area of Science:

  • Hematology
  • Oncology

Background:

  • Multiple myeloma is a plasma cell malignancy affecting over 10% of bone marrow.
  • Monoclonal immunoglobulins produced by myeloma cells are detectable via electrophoresis.
  • Clinical presentation commonly includes bone pain from lytic lesions, but incidental diagnosis occurs in up to 30% of cases.

Purpose of the Study:

  • To summarize the key aspects of multiple myeloma, including its presentation, diagnosis, differential diagnoses, and treatment outcomes.

Main Methods:

  • Review of existing literature and clinical knowledge regarding multiple myeloma.
  • Identification of diagnostic criteria and common presentations.
  • Summary of standard and alternative treatment modalities.
  • Analysis of treatment response rates and survival data.

Related Experiment Videos

Main Results:

  • Common symptoms include bone pain; incidental diagnoses and pathologic fractures are also frequent.
  • Differential diagnosis involves distinguishing multiple myeloma from other monoclonal gammopathies.
  • Standard treatment (melphalan-prednisone) and other modalities yield response rates of 50-60%.

Conclusions:

  • Multiple myeloma requires differentiation from other plasma cell disorders.
  • Current treatments have moderate efficacy, with an aggregate median survival of three years.